DIFFUSION PHARMACEUTICALS IN (DFFN) Stock Price, Forecast & Analysis
USA - NASDAQ:DFFN - US2537484048 - Common Stock
DFFN Key Statistics, Chart & Performance
The current stock price of DFFN is 4.4 USD. In the past month the price increased by 43.79%. In the past year, price decreased by -33.83%.
DFFN Latest News, Press Relases and Analysis
DFFN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.15 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About DFFN
Company Profile
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The company is headquartered in Charlottesville, Virginia and currently employs 13 full-time employees. The company went IPO on 2016-11-09. The firm is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.
Company Info
DIFFUSION PHARMACEUTICALS IN
300 East Main Street, Suite 201
Charlottesville VIRGINIA 22902 US
CEO: Robert J. Cobuzzi
Employees: 13
Phone: 14342200718.0
DIFFUSION PHARMACEUTICALS IN / DFFN FAQ
Can you describe the business of DIFFUSION PHARMACEUTICALS IN?
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The company is headquartered in Charlottesville, Virginia and currently employs 13 full-time employees. The company went IPO on 2016-11-09. The firm is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.
Can you provide the latest stock price for DIFFUSION PHARMACEUTICALS IN?
The current stock price of DFFN is 4.4 USD. The price increased by 11.68% in the last trading session.
Does DIFFUSION PHARMACEUTICALS IN pay dividends?
DFFN does not pay a dividend.
What is the ChartMill rating of DIFFUSION PHARMACEUTICALS IN stock?
DFFN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for DIFFUSION PHARMACEUTICALS IN?
DIFFUSION PHARMACEUTICALS IN (DFFN) will report earnings on 2023-11-13.
DFFN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to DFFN. When comparing the yearly performance of all stocks, DFFN is a bad performer in the overall market: 74.15% of all stocks are doing better.
DFFN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DFFN. No worries on liquidiy or solvency for DFFN as it has an excellent financial health rating, but there are worries on the profitability.
DFFN Financial Highlights
Over the last trailing twelve months DFFN reported a non-GAAP Earnings per Share(EPS) of -6.41. The EPS increased by 47.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DFFN Forecast & Estimates
7 analysts have analysed DFFN and the average price target is 40.8 USD. This implies a price increase of 827.27% is expected in the next year compared to the current price of 4.4.